AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.64 |
Market Cap | 45.15M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.76 |
PE Ratio (ttm) | -0.93 |
Forward PE | n/a |
Analyst | Buy |
Ask | 1.65 |
Volume | 172,577 |
Avg. Volume (20D) | 3,077,850 |
Open | 1.63 |
Previous Close | 1.60 |
Day's Range | 1.60 - 1.70 |
52-Week Range | 0.81 - 3.02 |
Beta | undefined |
About ITRM
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company ...
Analyst Forecast
According to 1 analyst ratings, the average rating for ITRM stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 204.75% from the latest price.
2 months ago · seekingalpha.com
Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript)Iterum Therapeutics plc (NASDAQ:ITRM ) U.S. FDA Approval of ORLYNVAH October 28, 2024 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs & Secretary Corey Fishman - President, Directo...